ClinicalTrialsFinder
RecruitingPhase 2NCT05541822

To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation

A Phase 2 Multicenter, Open-Label, Parallel Cohort Expansion Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-Mesenchymal-epithelial Transition Factor (c-MET) Dysregulation

Sponsor

Abion Inc

Enrollment

178 participants

Start Date

Jan 17, 2023

Study Type

INTERVENTIONAL

Conditions

Advanced Solid Tumors

Summary

ABN401-003 is a Phase 2 clinical study to assess efficacy, safety, tolerability and pharmacokinetic profile of ABN401 (vabametkib) in specific populations of advance solid tumors with c-MET alterations as monotherapy.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Lazertinib and a drug called Vabametkib for people with advanced solid tumors. The study is currently recruiting participants at 24 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGVabametkib

Tablets Route of Administration: Oral

DRUGLazertinib

Tablets Route of Administration: Oral

Locations(24)

Cancer Care of North Florida, PA (Lake City Cancer Care, LLC) - Medical Oncology

Lake City, Florida, United States

Mid Florida Center

Orange City, Florida, United States

The Henry Ford Cancer Institute

Detroit, Michigan, United States

The University of Texas MD Anderson Cancer Center

Houston, Texas, United States

National Cancer Center

Goyang-si, Gyeonggi-do, South Korea

Ajou University Hospital

Suwon, Gyeonggi-do, South Korea

Boramae Medical Center

Dongjak, Seoul, South Korea

Korea University Anam Hospital

Seoul, Seoul, South Korea

Severance Hospital

Sinchon-dong, Seoul, South Korea

Chungbuk National University Hospital

Cheongju-si, South Korea

Gachon University Gil Medical Center

Incheon, South Korea

Gyeongsang National University Hospital

Jinju, South Korea

Seoul National University Bundang Hospital

Seongnam-si, South Korea

Kangbuk Samsung Hospital

Seoul, South Korea

Asan Medical Center

Seoul, South Korea

Samsung Medical Center

Seoul, South Korea

The Catholic University of Korea, Seoul St Mary's Hospitals

Seoul, South Korea

The Catholic University of Korea St Vincents Hospital

Suwon, South Korea

China Medical University Hospital

Taichung, Taiwan

National Cheng Kung University Hospital

Tainan, Taiwan

Chi Mei Hospital, Liouying

Tainan, Taiwan

National Taiwan University Cancer Center (NTUCC)

Taipei, Taiwan

National Taiwan University Hospital

Taipei, Taiwan

Taipei Veterans General Hospital

Taipei, Taiwan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05541822

Related Trials

Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma

NCT064455174 locations

Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

NCT042224132 locations

A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors

NCT074603758 locations

A Study of ASP1002 in Adults for Treatment of Solid Tumors

NCT0571955815 locations

A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation

NCT0717291911 locations